SB-258719

From Wikipedia, the free encyclopedia
  (Redirected from SB-258,719)
Jump to: navigation, search
SB-258719
SB-258719 structure.png
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C18H32N2O2S
Molar mass 340.523 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT7 receptor partial inverse agonist,[1] and was the first such ligand identified for 5-HT7.[2] Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.[3][4][5][6]

References[edit]

  1. ^ Mahé C; Loetscher E; Feuerbach D; Müller W; Seiler MP; Schoeffter P (July 2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". European Journal of Pharmacology. 495 (2-3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157. 
  2. ^ Forbes IT; Dabbs S; Duckworth DM; Jennings AJ; King FD; Lovell PJ; Brown AM; Collin L; Hagan JJ; Middlemiss DN; Riley GJ; Thomas DR; Upton N (February 1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". Journal of Medicinal Chemistry. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592. 
  3. ^ Brenchat A; Romero L; García M; Pujol M; Burgueño J; Torrens A; Hamon M; Baeyens JM; Buschmann H; Zamanillo D; Vela JM (February 2009). "5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice". Pain. 141 (3): 239–47. doi:10.1016/j.pain.2008.11.009. PMID 19118950. 
  4. ^ Yanarates O; Dogrul A; Yildirim V; Sahin A; Sizlan A; Seyrek M; Akgül O; Kozak O; Kurt E; Aypar U (March 2010). "Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways". Anesthesiology. 112 (3): 696–710. doi:10.1097/ALN.0b013e3181cd7920. PMID 20179508. 
  5. ^ Brenchat A; Nadal X; Romero L; Ovalle S; Muro A; Sánchez-Arroyos R; Portillo-Salido E; Pujol M; Montero A; Codony X; Burgueño J; Zamanillo D; Hamon M; Maldonado R; Vela JM (June 2010). "Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity". Pain. 149 (3): 483–94. doi:10.1016/j.pain.2010.03.007. PMID 20399562. 
  6. ^ Brenchat A; Ejarque M; Zamanillo D; Vela JM; Romero L (August 2011). "Potentiation of Morphine Analgesia by Adjuvant Activation of 5-HT(7) Receptors". Journal of Pharmacological Sciences. 116 (4): 388–91. doi:10.1254/jphs.11039sc. PMID 21778664.